NCT00915785View on ClinicalTrials.gov

Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2013

Conditions
Myelodysplastic SyndromesLeukemia, Myeloid, Acute
Interventions
DRUG

5 azacytidine

Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.

Trial Locations (1)

SE5 9RS

King's College Hospital NHS Foundation Trust, London

All Listed Sponsors
lead

King's College London

OTHER

NCT00915785 - Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities | Biotech Hunter | Biotech Hunter